The inclusion of chronic kidney disease, estimated glomerular filtration rate measurement, and urine albumin-to-creatinine ratio should be considered as endpoints in atrial fibrillation, as should conventional major adverse cardiovascular events components, and integrated cardiorenal treatment should be prioritized. This evidence concerns the gene ALB and atrial fibrillation.